HYL — Hyloris Pharmaceuticals SA Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Hyloris Pharmaceuticals SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-11.6	-11.9	-15.4	-6.34	-6.33
Depreciation
Non-Cash Items	0.769	0.666	0.041	0.206	-1.14
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-0.577	-1.98	2.18	-1.42	-0.436
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-11.3	-13	-12.8	-6.9	-6.99
Capital Expenditures	-1.06	-0.739	-0.75	-0.297	-0.629
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-2.01	-10.6	10.6	0.556	-1.5
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-3.08	-11.4	9.89	0.259	-2.13
Financing Cash Flow Items	—	12.5	-0.012	0	-0.092
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-0.062	7.84	-0.131	-0.168	-0.431
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-14.4	-16.6	-3.05	-6.81	-9.82